Pronto to Distribute Signal's Myeloma Test | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Myeloma Health's parent company Signal Genetics said today that Pronto Diagnostics will distribute the Signal Myeloma Prognostic Risk Signature (MyPRS) test in Israel, under an exclusive agreement.

Tel Aviv-based Pronto provides molecular diagnostics-based oncology disease tests and genetic test kits, and it serves as a distributor for Pathwork Diagnostics and Epigenomics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.